(Q34990604)

5 August 2017

title

The cost-effectiveness of screening for chronic hepatitis B infection in the United States (English)

1 reference

cost-effectiveness analysis

5 August 2017

main subject

United States of America

0 references

1 reference

1 reference

1 reference

Mark H Eckman

1

1 reference

5 August 2017

Tiffany E Kaiser

series ordinal

2

1 reference

5 August 2017

Kenneth E Sherman

series ordinal

3

1 reference

5 August 2017

language of work or name

English

0 references

publication date

2 May 2011

1 reference

Clinical Infectious Diseases

5 August 2017

published in

1 reference

5 August 2017

volume

52

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1294-1306

1 reference

National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Health-state utilities in liver disease: a systematic review.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

The natural history of chronic hepatitis B virus infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Lamivudine for patients with chronic hepatitis B and advanced liver disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Cost-effectiveness in hepatitis B.

8 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Correlation between serum transaminase activity and virus load among patients with chronic liver disease type B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Clinicopathological features of incidental hepatocellular carcinoma in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Chronic hepatitis B--new goals, new treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Cost of chronic hepatitis B infection in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Assessment of utilities and health-related quality of life in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR199

Recommendations for identification and public health management of persons with chronic hepatitis B virus infection

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3097367

Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994

26 October 2018

1 reference

12 December 2020

Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years

1 reference

12 December 2020

Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites

1 reference

12 December 2020

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

1 reference

12 December 2020

Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases

1 reference

12 December 2020

Surveillance for acute viral hepatitis--United States, 2005

1 reference

12 December 2020

Decision Maker 3.0. Improved decision analysis by personal computer

1 reference

12 December 2020

Identifiers

DOI

10.1093/CID/CIR199

1 reference

5 August 2017

1 reference

5 August 2017

1 reference